We formulate and analyze a mathematical model describing immune response to avascular tumor under the influence of immunotherapy and chemotherapy and their combinations as well as vaccine treatments. The effect of vaccine therapy is considered as a parametric perturbation of the model. In the case of a weak immune response, neither immunotherapy nor chemotherapy is found to cause tumor regressi...

Certain chemotherapeutic drugs, such as cyclophosphamide (CTX), can enhance the antitumor efficacy of immunotherapy because of their capacity to modulate innate and adaptive immunity. Indeed, it has been argued that this capacity may be more significant to chemotherapeutic efficacy in general than is currently appreciated. To gain insights into the core mechanisms of chemoimmunotherapy, we meth...

BACKGROUND Many patients with aggressive B-cell lymphomas and high clinical risk score still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized that intensified chemoimmunotherapy including systemic central nervous system (CNS) prophylaxis improves outcome and reduces the incidence of CNS-related events. PATIENTS AND METHODS Inclusion criteria were age 18-65 years, ...

Mantle cell lymphoma (MCL) is an infrequent subtype of non-Hodgkin's lymphoma (NHL) and represents between 4-8% of adult lymphomas. Recently an increase in its incidence to 1-2 cases/100,000 inhabitants/year has been observed. The first line of treatment is based on chemoimmunotherapy and depends on age and the initial stage at diagnosis. There are no second line or successive treatments. There...

*Author for correspondence: [email protected] Cancer is one leading cause of mortality that is associated with genetic background or environmental toxin [1]. Multiple anti-cancer therapies have been developed and applied clinically such as surgery, chemotherapy, radiotherapy, therapeutic antibody, small molecule, Antibody-Drug Conjugate (ADC), cellular immunotherapy, chemoimmunotherapy, and radioimm...

The last 10 years of clinical investigation in chronic lymphocytic leukemia (CLL) have established the efficacy of front-line chemoimmunotherapy in inducing remission; improving progression-free survival (PFS); and, with the addition of anti-CD20 antibodies, improving overall survival (OS).[1-3] For fit patients, the optimal regimen has recently been confirmed to be fludarabine, cyclophosphamid...